Physicians' Academy for Cardiovascular Education
Member

PCSK9 expert opinions

This series of PCSK9 Expert Opinions is aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice.

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA
Prof. Wolfgang Koenig argues that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
Prof. Richard Hobbs states that PCSK9 inhibition reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy and puts the data into perspective of other trials and molecules.

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Prof. John Kastelein argues that after FOURIER and SPIRE 1&2, there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2 and the implications for LDL-c lowering in high-CV risk individuals.

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.